Vaginal atrophy can affect every aspect of your patients’ lives
Vaginal atrophy is very common, with about 50% of postmenopausal women having pain or discomfort due to the condition.1,2
The wide range of effects that women can experience can affect everything from their well-being and quality of life to their self-image and personal relationships.1,2
Women who have vaginal atrophy can have diverse symptoms, such as vaginal dryness, dyspareunia, itching, dysuria and burning.3
My Blissel® Time to talk
Video Library
A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics including, the signs and symptoms of VA, how to make the diagnosis and the impact of vaginal atrophy on a patient’s quality of life.
Women need support and treatment guidance
It can be difficult for women seeking information about vaginal atrophy to talk about the condition, as they may want their doctor to start the conversation.4
The reasons why women feel they cannot talk to their doctor about vaginal atrophy are varied, but can include feeling embarrassed, thinking that there is no treatment, and feeling that the discussion of these symptoms is not appropriate.5
Local therapy is clearly stated to be preferable to systemic hormonal treatment in NICE guidelines for vaginal symptoms.6 Guidance states that vaginal oestrogen should be offered to women to manage the bothersome symptoms of vaginal atrophy.6
Despite this, half of all women with postmenopausal genitourinary symptoms have not been prescribed any therapies for their symptoms.7
Using Blissel® to treat vaginal atrophy
Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, which is indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.8,9
The treatment is well tolerated and effective for postmenopausal vaginal atrophy.9 Your patients may notice a rapid improvement in their symptoms from the initial days of treatment when you prescribe Blissel®.10
Prescribe Blissel® by brand for your patients. Blissel®is the first and only prescribable estriol containing gel for the treatment of vaginal atrophy1,2
Guidelines on the treatment of vaginal atrophy
NICE guidelines provide clear direction that local therapy is preferable to systemic treatment for vaginal symptoms.6 Guidelines advocate to provide vaginal oestrogen to women to manage bothersome symptoms of vaginal atrophy.6
Despite clear guidelines, half of all women who experience genitourinary symptoms after the menopause have not received any treatment at all for their symptoms.7
Treating vaginal atrophy with Blissel®
Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.8,9
For postmenopausal vaginal atrophy, the treatment has been shown to be well-tolerated and effective.9 Blissel® gives your patients a rapid improvement in their symptoms from the first days of treatment.10
Upcoming Webinars 2024
26th Nov
7pm to
9pm
Navigating Menopause: A comprehensive overview with Nurse Consultant Nikki Noble.
- Introduction to menopause and its impact on genitourinary health.
- Identification and assessment of genitourinary symptoms.
- Overview of the medical management landscape.
- Q&A session.
How BlisselⓇ
Works
Efficacy
Dosing
Ultra low dose estriol vaginal gel8,9
Prescribing and Adverse event reporting information for BlisselⓇ can be found here.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com
1. Nappi RE, Palacios S. Climacteric. 2014;17:3–9. 2. Moral E, et al. Menopause. 2018;25(12):1418-23.
3. Palmaa F, et al. Maturitas. 2018;108:18–23. 4. Krychman M, et al. J Sex Med 2017;14:425-433.
5. Kagan R, et al. Drugs Aging. 2019;36:897–908. 6. NICE. Menopause: diagnosis and management (NG23). Available from: https://
www.nice.org.uk/guidance/ng23/chapter/recommendations. Accessed December 2023.
7. NAMS position statement. Menopause. 2020;27(9):976-92. 8. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.
9. Cano A, et al. Menopause. 2012;19(10):1130-9. 10. Lázaro-Carrasco de la Fuente J, et al. J Menopausal Med. 2022;28(2):60-69.
Date of preparation: Oct 2024 | UK-BLS-584